Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism

Clinica Chimica Acta

Volumn 413, Issue 1-2, 2012, Pages 160-165

  Hanada, Hiroyuki ^a   Mugii, Satomi ^a   Okubo, Manabu ^a   Maeda, Ikuhiro ^a   Kuwayama, Kazuya ^b   Hidaka, Yoh ^c   Kitazume Taneike, Rika ^c   Yamashita, Taiji ^c   Kawase, Ryota ^c   Nakaoka, Hajime ^c   Inagaki, Miwako ^c   Yuasa Kawase, Miyako ^c   Nakatani, Kazuhiro ^c   Tsubakio Yamamoto, Kazumi ^c   Masuda, Daisaku ^c   Ohama, Tohru ^c   Matsuyama, Akifumi ^d   Ishigami, Masato ^c   Nishida, Makoto ^e   Komuro, Issei ^c   Yamashita, Shizuya ^c   more..

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b Minami Osaka General Hospital   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

Apolipoprotein B 48 (apoB 48); Chemiluminescence enzyme immunoassay; Chylomicron remnants; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN B48; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; CHEMOLUMINESCENCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRINKING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIFESTYLE MODIFICATION; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEIN B-48; CHYLOMICRONS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIMIT OF DETECTION; LUMINESCENCE; MALE; METABOLIC SYNDROME X; REPRODUCIBILITY OF RESULTS;

EID: 82955212918     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.09.013     Document Type: Article

References (23)

1. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
2. Yu K.C., Cooper A.D. Postprandial lipoproteins and atherosclerosis. Front Biosci 2001, 6:D332-D354.
3. Phillips M.L., Pullinger C., Kroes I., Kroes J., Hardman D.A., Chen G. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J Lipid Res 1997, 38:1170-1177.
4. Uchida Y., Kurano Y., Ito S. Establishment of monoclonal antibody against human ApoB-48 and measurement of ApoB-48 in serum by ELISA method. J Clin Lab Anal 1998, 12:289-292.
5. Sakai N., Uchida Y., Ohashi K., et al. Measurement of fasting serum apoB-48 concentrations in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 2003, 44:1256-1262.
6. NCCLS. Protocols for determination of limits of detection; approved guideline 2004. NCCLS document EP17-A (ISBN 1-56238-551-8).
7. Metabolic Syndrome Diagnosis Standard Advisory Committe Definition and diagnostic norm of metabolic syndrome. JJSIM 2005, 94:794-809.
8. Yamane M., Jiao S., Kihara S., et al. Increased proportion of plasma apoB-48 to apoB-100 in non-insulin-dependent diabetic rats: contribution of enhanced apoB mRNA editing in the liver. J Lipid Res 1995, 36:1676-1685.
9. Masuda D., Hirano K., Oku H., et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res 2009, 50:999-1011.
10. Tanimura K., Nakajima Y., Nagao M., et al. Association of serum apolipoprotein B48 concentration with the presence of carotid plaque in type 2 diabetes mellitus. Diabetes Res Clin Pract 2008, 81:338-344.
11. Mugii S., Hanada H., Takeoka K., Hidaka Y., Masuda D., Ohama T., Toyama Y., Yamashita S. Clinical significance of apolipoprotein B-48 (apoB-48) in patients with thyroid disease. Rinsho Byori 2009, 57:1058-1063. in Japanese.
12. Meyer E., Westerveld H.T., de Ruyter-Meijstek F.C., et al. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: a case-control study. Atherosclerosis 1996, 124:221-235.
13. Simpson H.S., Williamson C.M., Olivecrona T., et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990, 85:193-202.
14. Karpe F., Steiner G., Uffelman K., Olivecrona T., Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994, 106:83-97.
15. Daoletti R., Bolego C., Poli A., Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag 2006, 2:145-152.
16. Yamada N. Metabolic syndrome: overview. JJCLA 2008, 33:149-152.
17. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., Rimm E.B. Plasma adiponectin concentrations and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
18. Fujioka Y., Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009, 16:145-154.
19. Nakatani K., Sugimoto T., Masuda D., Okano R., Oya T., Monden Y., Yamashita T., Kawase R., Nakaoka H., Inagaki M., Yuasa-Kawase M., Tsubakio-Yamamoto K., Ohama T., Nishida M., Ishigami M., Komuro I., Yamashita S. Serum apolipoprotein B-48 concentrations are correlated with carotid intima-media thickness in subjects with normal serum triglyceride concentrations. Atherosclerosis 2011, 218(1):226-232.
20. Kawakami A., Tanaka A., Nakano T., Saniabadi A., Numano F. Stimulation of arterial smooth muscle cell proliferation by remnant lipoprotein particles isolated by immuno-affinity chromatography with anti-apo A-I and anti-apo B-100. Horm Metab Res 2001, 33:67-72.
21. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like particles in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gel. Clin Chim Acta 1993, 223:53-71.
22. Sato I., Fujioka Y., Hayashi F., et al. Fundamental evaluation of apolipoprotein B-48 by chemiluminescence enzyme immunoassay-identification of apolipoprotein B-48 with immunoblotting. Rinsho Byori 2007, 55:528-533. (in Japanese).
23. Smith D., Watts G.F., Dane-Stewart C., Mamo J.C. Postprandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Cli Invest 1999, 29:203-209.